JP2019519584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519584A5 JP2019519584A5 JP2018568771A JP2018568771A JP2019519584A5 JP 2019519584 A5 JP2019519584 A5 JP 2019519584A5 JP 2018568771 A JP2018568771 A JP 2018568771A JP 2018568771 A JP2018568771 A JP 2018568771A JP 2019519584 A5 JP2019519584 A5 JP 2019519584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- item
- patient
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 18
- 229960001467 bortezomib Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 13
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 13
- 229940068977 polysorbate 20 Drugs 0.000 claims description 13
- 208000023761 AL amyloidosis Diseases 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 12
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 12
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 12
- 230000000747 cardiac effect Effects 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 229960003957 dexamethasone Drugs 0.000 claims description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 12
- 229960004942 lenalidomide Drugs 0.000 claims description 12
- 229960001924 melphalan Drugs 0.000 claims description 12
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 12
- 229960004618 prednisone Drugs 0.000 claims description 12
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102400001263 NT-proBNP Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 37
- 238000000034 method Methods 0.000 description 36
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106974A JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357151P | 2016-06-30 | 2016-06-30 | |
| US62/357,151 | 2016-06-30 | ||
| PCT/US2017/040289 WO2018005967A1 (en) | 2016-06-30 | 2017-06-30 | Compositions for treating amyloidosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106974A Division JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519584A JP2019519584A (ja) | 2019-07-11 |
| JP2019519584A5 true JP2019519584A5 (enExample) | 2020-08-13 |
Family
ID=59351103
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568771A Withdrawn JP2019519584A (ja) | 2016-06-30 | 2017-06-30 | アミロイドーシスを処置するための組成物 |
| JP2022106974A Withdrawn JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A Pending JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106974A Withdrawn JP2022121658A (ja) | 2016-06-30 | 2022-07-01 | アミロイドーシスを処置するための組成物 |
| JP2024108049A Pending JP2024127990A (ja) | 2016-06-30 | 2024-07-04 | アミロイドーシスを処置するための組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190169280A1 (enExample) |
| EP (1) | EP3478713B1 (enExample) |
| JP (3) | JP2019519584A (enExample) |
| CY (1) | CY1125536T1 (enExample) |
| DK (1) | DK3478713T3 (enExample) |
| ES (1) | ES2914781T3 (enExample) |
| HR (1) | HRP20220979T8 (enExample) |
| HU (1) | HUE059400T2 (enExample) |
| LT (1) | LT3478713T (enExample) |
| MA (1) | MA45552A (enExample) |
| PL (1) | PL3478713T3 (enExample) |
| PT (1) | PT3478713T (enExample) |
| RS (1) | RS63446B1 (enExample) |
| SI (1) | SI3478713T1 (enExample) |
| SM (1) | SMT202200261T1 (enExample) |
| WO (1) | WO2018005967A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092264A1 (ru) * | 2018-03-23 | 2020-12-03 | Протена Байосайенсиз Лимитед | Лечение и профилактика амилоидоза |
| CN113924099A (zh) * | 2019-02-12 | 2022-01-11 | 普罗塞纳生物科学有限公司 | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 |
| JP7619953B2 (ja) * | 2019-03-05 | 2025-01-22 | プロシーナ バイオサイエンシーズ リミテッド | Ａｌアミロイドーシスを処置する方法 |
| WO2021041884A1 (en) * | 2019-08-30 | 2021-03-04 | Alnylam Pharmaceuticals, Inc. | Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy |
| TW202216768A (zh) * | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| ES2544679T3 (es) | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Tratamiento y profilaxis de la amiloidosis |
| PE20191242A1 (es) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
-
2017
- 2017-06-30 HR HRP20220979TT patent/HRP20220979T8/hr unknown
- 2017-06-30 PT PT177402005T patent/PT3478713T/pt unknown
- 2017-06-30 EP EP17740200.5A patent/EP3478713B1/en active Active
- 2017-06-30 JP JP2018568771A patent/JP2019519584A/ja not_active Withdrawn
- 2017-06-30 SM SM20220261T patent/SMT202200261T1/it unknown
- 2017-06-30 DK DK17740200.5T patent/DK3478713T3/da active
- 2017-06-30 US US16/314,143 patent/US20190169280A1/en not_active Abandoned
- 2017-06-30 SI SI201731146T patent/SI3478713T1/sl unknown
- 2017-06-30 LT LTEPPCT/US2017/040289T patent/LT3478713T/lt unknown
- 2017-06-30 WO PCT/US2017/040289 patent/WO2018005967A1/en not_active Ceased
- 2017-06-30 HU HUE17740200A patent/HUE059400T2/hu unknown
- 2017-06-30 MA MA045552A patent/MA45552A/fr unknown
- 2017-06-30 RS RS20220716A patent/RS63446B1/sr unknown
- 2017-06-30 ES ES17740200T patent/ES2914781T3/es active Active
- 2017-06-30 PL PL17740200.5T patent/PL3478713T3/pl unknown
-
2020
- 2020-09-25 US US17/032,884 patent/US20210079078A1/en not_active Abandoned
-
2022
- 2022-07-01 JP JP2022106974A patent/JP2022121658A/ja not_active Withdrawn
- 2022-08-08 CY CY20221100542T patent/CY1125536T1/el unknown
-
2024
- 2024-07-04 JP JP2024108049A patent/JP2024127990A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12296008B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP2019519584A5 (enExample) | ||
| Malone et al. | The immune system and stroke: from current targets to future therapy | |
| RU2721910C2 (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| AU2016250388B2 (en) | Treatment for rheumatoid arthritis | |
| US20230303677A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2018515493A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| CN105251004A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2015517512A (ja) | Ｃｄ３７抗体の更なる薬剤との併用 | |
| JP2019532970A5 (enExample) | ||
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2020502218A5 (enExample) | ||
| JP2022520572A (ja) | 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 | |
| JP2023551733A (ja) | 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの併用免疫療法 | |
| US20160022777A1 (en) | Combination therapy with il-12 | |
| US20160106837A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| US20230338496A1 (en) | Vaccination against diabetes, obesity and complications thereof | |
| US11623003B2 (en) | Vaccination against diabetes, obesity and complications thereof | |
| US10925951B2 (en) | Vaccination against diabetes, obesity and complications thereof |